Pharmacogenomics of Heparin-Induced Thrombocytopenia

Conditions

• Heparin-induced Thrombocytopenia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Blood Draw — PROCEDURE
  A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.

Study Details

The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.

Key Dates

Start date

Mar 31, 2016

Status verified

Jun 2024

Primary completion

Jul 31, 2026

Completion

Jul 31, 2026

Study Design

Enrollment

125 participants (estimated)

Arms

• Arm: Blood Draw
  A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).

Primary Outcome Measure

Serotonin Release Assay [ Time Frame: 0-30 days ]

Central Contacts

• Jason H Karnes, PharmD, PhD
  520-626-1447
  [email protected]
• Talin A Robinson-Catalan, MS
  520-278-6114
  [email protected]

Locations (1)

Find similar trials in Tucson, AZ